Compounds > lapatinib
Page last updated: 2024-09-05

lapatinib and ixabepilone

lapatinib has been researched along with ixabepilone in 6 studies

Compound Research Comparison

Studies
(lapatinib)		Trials
(lapatinib)		Recent Studies (post-2010)
(lapatinib)		Studies
(ixabepilone)		Trials
(ixabepilone)		Recent Studies (post-2010) (ixabepilone)
1,9193051,442283101116

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Heinemann, V; Stemmler, HJ1
Halterman, PA1
Schwartz, J1
Egerton, N1
Al-Zubaidi, Y; Bourget, K; Murray, M; Rahman, MK; Tam, S; Zhou, F1

Reviews

5 review(s) available for lapatinib and ixabepilone

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
[Oncology 2008].
    Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:25-26

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Combined Modality Therapy; Disease Progression; Epothilones; Humans; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate

2008
Lapatinib and ixabepilone for the treatment of metastatic breast cancer.
    Pharmacotherapy, 2008, Volume: 28, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Epothilones; Female; Humans; Lapatinib; Neoplasm Metastasis; Quinazolines

2008
Current combination chemotherapy regimens for metastatic breast cancer.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2009, Dec-01, Volume: 66, Issue:23 Suppl 6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Breast Neoplasms; Capecitabine; Cytotoxins; Deoxycytidine; Diarrhea; Drug Delivery Systems; Epothilones; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Signal Transduction; Skin Diseases; Trastuzumab

2009
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Marrow; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Interactions; Epothilones; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lymphatic Metastasis; Peripheral Nervous System Diseases; Quinazolines; Treatment Failure; Treatment Outcome; Tubulin Modulators

2010

Other Studies

1 other study(ies) available for lapatinib and ixabepilone

ArticleYear
The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.
    Pharmacological reports : PR, 2022, Volume: 74, Issue:5

    Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Triple Negative Breast Neoplasms

2022